VYNE Therapeutics Inc.
685 Route 202/206 N., Suite 301
Bridgewater, New Jersey 08807
November 20, 2023
Via Edgar
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attn: Doris Stacey Gama
RE: VYNE Therapeutics Inc.
Registration Statement on Form S-3
File No. 333-275507
Acceleration Request
Requested Date: November 22, 2023
Requested Time: 4:00 p.m. Eastern Time
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Exchange Act of 1933, as amended, the undersigned registrant hereby requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to cause the above-referenced Registration Statement on Form S-3 (File No. 333-275507) (the “Registration Statement”) to become effective at 4:00 p.m. Eastern Time on Wednesday, November 22, 2023, or as soon thereafter as is practicable, or at such other time as its legal counsel, Cooley LLP, may request by telephone to the staff of the Commission.
Once the Registration Statement has been declared effective, please orally confirm that event with Mark Ballantyne of Cooley LLP, counsel to the Registrant, at (703) 456-8084, or in his absence, Minkyu Park, at (212) 479-6588.
[Signature page follows]
| Sincerely, | ||
| VYNE Therapeutics Inc. | ||
| By: | /s/ David Domzalski | |
| David Domzalski | ||
| Chief Executive Officer | ||
| cc: | Tyler Zeronda, Chief Financial Officer, VYNE Therapeutics Inc. |
Brian Leaf, Cooley LLP
Mark Ballantyne, Cooley LLP
Minkyu Park, Cooley LLP
